Track NewAmsterdam Pharma Company N.V. Ordinary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NewAmsterdam Pharma Company N.V. Ordinary Shares NAMS · Stock Open NewAmsterdam Pharma Company N.V. Ordinary Shares in new tab

20.14 USD
EPS
-1.69
P/B
3.59
ROE
-30.16
Beta
0.15
Target Price
50.23 USD
Loading chart...
Key Metrics
Earnings dateFeb. 17, 2027
EPS-1.69
Book Value5.26
Price to Book3.59
Debt/Equity0.01
% Insiders0.893%
Growth
Revenue Growth54.07%
Estimates
Forward P/E-11.19
Forward EPS-1.69
Target Mean Price50.23

DCF valuation

Model fair value for NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
Result
Sign in to run the valuation for NAMS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
14 analysts · consensus Strong buy · mean target 50.23 USD (low 38.16, high 59.29) · as of 9 Nov 2026
Low 38.16
Mean 50.23
High 59.29
Price 20.14
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

NewAmsterdam Pharma Company N.V. Ordinary Shares Logo NewAmsterdam Pharma Company N.V. Ordinary Shares Analysis (NAMS)

Netherlands Health Care Official Website Stock

Is NewAmsterdam Pharma Company N.V. Ordinary Shares a good investment? NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is currently trading at 20.14 USD. Market analysts have a consensus price target of 50.23 USD. This suggests a potential upside from current levels.

Earnings Schedule: NewAmsterdam Pharma Company N.V. Ordinary Shares is expected to release its next earnings report on Feb. 17, 2027. The market consensus estimate for Forward EPS is -1.69.

Investor FAQ

Does NewAmsterdam Pharma Company N.V. Ordinary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is NewAmsterdam Pharma Company N.V. Ordinary Shares?

NewAmsterdam Pharma Company N.V. Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 17, 2027. The company currently has a trailing EPS of -1.69.

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Exchange Ticker
NMS (United States) NAMS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion